Recent studies have revealed that CEMA, as an acrolein exposure biomarker, could decrease insulin sensitivity and raise fasting insulin FPI, FPG, HOMA-insulin resistance, risks of prevalent IR, impaired fasting glucose, impaired fasting glucose (IFG), and the risk of type 2 diabetes, respectively (27). The gene discussed is INS; the disease is Insulin resistance.